📰 Varoglutamstat Clinical Program News
Varoglutamstat Clinical Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Varoglutamstat Clinical Program. Real-time updates on events, politics, business and more.
April 24, 2024
24.04.2024 - Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date ...
July 16, 2023
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s...
May 16, 2023
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext
May 16, 2023
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext
April 19, 2023
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and...
April 19, 2023
Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights
April 19, 2023
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND